questionsmedicales.fr
Lipides
Lipides membranaires
Sphingolipides
Glycosphingolipides
Glycosphingolipides acides
Gangliosides
Gangliosides : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Gangliosides : Questions médicales les plus fréquentes",
"headline": "Gangliosides : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Gangliosides : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-06",
"dateModified": "2025-03-31",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Gangliosides"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Glycosphingolipides acides",
"url": "https://questionsmedicales.fr/mesh/D020384",
"about": {
"@type": "MedicalCondition",
"name": "Glycosphingolipides acides",
"code": {
"@type": "MedicalCode",
"code": "D020384",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D10.570.877.360.025"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Ganglioside GM1",
"alternateName": "G(M1) Ganglioside",
"url": "https://questionsmedicales.fr/mesh/D005677",
"about": {
"@type": "MedicalCondition",
"name": "Ganglioside GM1",
"code": {
"@type": "MedicalCode",
"code": "D005677",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D10.570.877.360.025.475.390"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Ganglioside GM2",
"alternateName": "G(M2) Ganglioside",
"url": "https://questionsmedicales.fr/mesh/D005678",
"about": {
"@type": "MedicalCondition",
"name": "Ganglioside GM2",
"code": {
"@type": "MedicalCode",
"code": "D005678",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D10.570.877.360.025.475.400"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Ganglioside GM3",
"alternateName": "G(M3) Ganglioside",
"url": "https://questionsmedicales.fr/mesh/D005679",
"about": {
"@type": "MedicalCondition",
"name": "Ganglioside GM3",
"code": {
"@type": "MedicalCode",
"code": "D005679",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D10.570.877.360.025.475.510"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Gangliosides",
"alternateName": "Gangliosides",
"code": {
"@type": "MedicalCode",
"code": "D005732",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Sandro Sonnino",
"url": "https://questionsmedicales.fr/author/Sandro%20Sonnino",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Italy. sandro.sonnino@unimi.it."
}
},
{
"@type": "Person",
"name": "Laura Mauri",
"url": "https://questionsmedicales.fr/author/Laura%20Mauri",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Italy."
}
},
{
"@type": "Person",
"name": "Jin-Ichi Inokuchi",
"url": "https://questionsmedicales.fr/author/Jin-Ichi%20Inokuchi",
"affiliation": {
"@type": "Organization",
"name": "Division of Glycopathology, Institute of Molecular Biomembrane and Glycobiology, Tohoku Medical and Pharmaceutical University, Sendai, Japan."
}
},
{
"@type": "Person",
"name": "Ronald L Schnaar",
"url": "https://questionsmedicales.fr/author/Ronald%20L%20Schnaar",
"affiliation": {
"@type": "Organization",
"name": "Departments of Pharmacology and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, United States."
}
},
{
"@type": "Person",
"name": "Massimo Aureli",
"url": "https://questionsmedicales.fr/author/Massimo%20Aureli",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Diagnostic accuracy of an iPad application for detection of visual field defects.",
"datePublished": "2022-09-05",
"url": "https://questionsmedicales.fr/article/36064770",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41433-022-02223-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Influence of Protective Headgear on the Visual Field of Recreational-Level Skiers.",
"datePublished": "2022-08-25",
"url": "https://questionsmedicales.fr/article/36078342",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph191710626"
}
},
{
"@type": "ScholarlyArticle",
"name": "Binocular visual field in adults with horizontal strabismus and driving requirements.",
"datePublished": "2022-12-02",
"url": "https://questionsmedicales.fr/article/36460857",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41433-022-02319-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "The resolution of face perception varies systematically across the visual field.",
"datePublished": "2024-05-13",
"url": "https://questionsmedicales.fr/article/38739635",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0303400"
}
},
{
"@type": "ScholarlyArticle",
"name": "Eye and head movements in visual search in the extended field of view.",
"datePublished": "2024-04-17",
"url": "https://questionsmedicales.fr/article/38632334",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-59657-5"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Lipides",
"item": "https://questionsmedicales.fr/mesh/D008055"
},
{
"@type": "ListItem",
"position": 3,
"name": "Lipides membranaires",
"item": "https://questionsmedicales.fr/mesh/D008563"
},
{
"@type": "ListItem",
"position": 4,
"name": "Sphingolipides",
"item": "https://questionsmedicales.fr/mesh/D013107"
},
{
"@type": "ListItem",
"position": 5,
"name": "Glycosphingolipides",
"item": "https://questionsmedicales.fr/mesh/D006028"
},
{
"@type": "ListItem",
"position": 6,
"name": "Glycosphingolipides acides",
"item": "https://questionsmedicales.fr/mesh/D020384"
},
{
"@type": "ListItem",
"position": 7,
"name": "Gangliosides",
"item": "https://questionsmedicales.fr/mesh/D005732"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Gangliosides - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Gangliosides",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Gangliosides",
"description": "Comment diagnostiquer une maladie liée aux gangliosides ?\nQuels tests sont utilisés pour détecter les gangliosides ?\nLes symptômes peuvent-ils indiquer un problème de gangliosides ?\nQuelle imagerie est utile pour évaluer les gangliosides ?\nLes antécédents familiaux sont-ils importants pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D005732?mesh_terms=Visual+Fields&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Gangliosides",
"description": "Quels sont les symptômes courants des gangliosidoses ?\nLes gangliosides affectent-ils le système nerveux ?\nPeut-on observer des symptômes cutanés ?\nLes troubles cognitifs sont-ils liés aux gangliosides ?\nLes douleurs musculaires sont-elles un symptôme ?",
"url": "https://questionsmedicales.fr/mesh/D005732?mesh_terms=Visual+Fields&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Gangliosides",
"description": "Peut-on prévenir les gangliosidoses ?\nLe conseil génétique est-il recommandé ?\nLes vaccinations peuvent-elles aider ?\nL'alimentation peut-elle jouer un rôle préventif ?\nLes tests de dépistage sont-ils utiles ?",
"url": "https://questionsmedicales.fr/mesh/D005732?mesh_terms=Visual+Fields&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Gangliosides",
"description": "Quels traitements existent pour les gangliosidoses ?\nLa thérapie génique est-elle une option ?\nLes médicaments peuvent-ils aider ?\nY a-t-il des traitements expérimentaux disponibles ?\nLe soutien nutritionnel est-il important ?",
"url": "https://questionsmedicales.fr/mesh/D005732?mesh_terms=Visual+Fields&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Gangliosides",
"description": "Quelles complications peuvent survenir ?\nLes gangliosidoses peuvent-elles entraîner des handicaps ?\nY a-t-il un risque accru de maladies associées ?\nLes complications sont-elles réversibles ?\nComment gérer les complications ?",
"url": "https://questionsmedicales.fr/mesh/D005732?mesh_terms=Visual+Fields&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Gangliosides",
"description": "Quels sont les facteurs de risque des gangliosidoses ?\nLes origines ethniques influencent-elles le risque ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLes antécédents médicaux familiaux sont-ils significatifs ?\nLes mutations génétiques sont-elles héréditaires ?",
"url": "https://questionsmedicales.fr/mesh/D005732?mesh_terms=Visual+Fields&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une maladie liée aux gangliosides ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests génétiques, des analyses biochimiques et des biopsies."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les gangliosides ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des analyses de tissus peuvent être effectués pour détecter les gangliosides."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils indiquer un problème de gangliosides ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes neurologiques ou musculaires peuvent suggérer une dysfonction des gangliosides."
}
},
{
"@type": "Question",
"name": "Quelle imagerie est utile pour évaluer les gangliosides ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM peut aider à visualiser les anomalies cérébrales associées aux gangliosidoses."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux sont-ils importants pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents familiaux de maladies génétiques peuvent orienter le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants des gangliosidoses ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des troubles neurologiques, des retards de développement et des problèmes moteurs."
}
},
{
"@type": "Question",
"name": "Les gangliosides affectent-ils le système nerveux ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les gangliosides sont essentiels pour le fonctionnement normal du système nerveux."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes cutanés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines gangliosidoses peuvent provoquer des lésions cutanées ou des anomalies pigmentaires."
}
},
{
"@type": "Question",
"name": "Les troubles cognitifs sont-ils liés aux gangliosides ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles cognitifs peuvent survenir en raison de l'accumulation de gangliosides dans le cerveau."
}
},
{
"@type": "Question",
"name": "Les douleurs musculaires sont-elles un symptôme ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs musculaires peuvent être présentes en raison de l'atteinte des gangliosides."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les gangliosidoses ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est limitée, mais le dépistage génétique peut aider à identifier les porteurs."
}
},
{
"@type": "Question",
"name": "Le conseil génétique est-il recommandé ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le conseil génétique est conseillé pour les familles à risque de gangliosidoses."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations ne préviennent pas les gangliosidoses, mais protègent contre d'autres maladies."
}
},
{
"@type": "Question",
"name": "L'alimentation peut-elle jouer un rôle préventif ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir la santé générale, mais ne prévient pas les gangliosidoses."
}
},
{
"@type": "Question",
"name": "Les tests de dépistage sont-ils utiles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests de dépistage peuvent identifier les porteurs de mutations génétiques."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les gangliosidoses ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la thérapie enzymatique, la gestion des symptômes et le soutien psychologique."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en cours d'étude pour certaines gangliosidoses, mais n'est pas encore standard."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent soulager les symptômes, mais ne traitent pas la cause sous-jacente."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux disponibles ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des essais cliniques sont en cours pour de nouveaux traitements des gangliosidoses."
}
},
{
"@type": "Question",
"name": "Le soutien nutritionnel est-il important ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un soutien nutritionnel peut aider à améliorer la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles neurologiques graves, des infections et des problèmes respiratoires."
}
},
{
"@type": "Question",
"name": "Les gangliosidoses peuvent-elles entraîner des handicaps ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines gangliosidoses peuvent entraîner des handicaps physiques ou mentaux permanents."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de maladies associées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent avoir un risque accru de maladies auto-immunes ou métaboliques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La plupart des complications des gangliosidoses ne sont pas réversibles et nécessitent une gestion."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite une approche multidisciplinaire incluant médecins et thérapeutes."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque des gangliosidoses ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des mutations génétiques et des origines ethniques spécifiques."
}
},
{
"@type": "Question",
"name": "Les origines ethniques influencent-elles le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines populations, comme les Ashkénazes, ont un risque plus élevé de gangliosidoses."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, les facteurs environnementaux ne sont pas clairement établis comme des risques."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux familiaux sont-ils significatifs ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents médicaux de maladies métaboliques augmentent le risque de gangliosidoses."
}
},
{
"@type": "Question",
"name": "Les mutations génétiques sont-elles héréditaires ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les mutations génétiques responsables des gangliosidoses sont souvent héréditaires."
}
}
]
}
]
}
Tablet-based perimetry could be used to test for glaucomatous visual field defects in settings without easy access to perimeters, although few studies have assessed diagnostic accuracy of tablet-based...
This was a prospective, cross-sectional study of patients undergoing their first Humphrey Field Analyser (HFA) visual field test at a glaucoma clinic in India. Participants underwent 24-2 SITA Standar...
203 eyes from 115 participants were included, with 82 eyes classified as moderate or worse glaucoma. iPad perimetry had an area under the receiver operating characteristic (AUROC) curve of 0.64 (95% C...
iPad perimetry using the visualFields Easy application had inadequate diagnostic accuracy to be used as a screening tool for glaucoma in this South Indian population....
The benefit of protective headgear for recreational skiers is an ongoing debate in the snow sports industry, and there are a lot of opposing opinions. Due to the dynamic conditions in which winter spo...
To determine the horizontal extent of the binocular visual field (BVF) in subjects with horizontal strabismus and whether the BVF falls below the driving standard....
Adults with congenital esotropia and infantile exotropia ≤45 Prism Dioptres (PD), and subjects with orthotropia were recruited. The manifest angle of deviation was measured using a simultaneous prism ...
Forty-nine subjects were included: 10 with orthotropia, 20 with exotropia and 19 with esotropia. The horizontal extent of BVF (degrees) was significantly smaller in esotropes (122.8 ± 18.8) than in or...
The horizontal extent of BVF is significantly smaller and more variable in adults with congenital esotropia and may fall below the driving standard....
Largest study on visual fields in subjects with horizontal strabismus including an orthotropic control group who do not have diplopia and who would otherwise meet the driving standard. Visual field qu...
The findings of this study would suggest that people with an esotropia should be offered the opportunity to have a binocular visual field test before applying for a driving license. The DVLA may want ...
Visual abilities tend to vary predictably across the visual field-for simple low-level stimuli, visibility is better along the horizontal vs. vertical meridian and in the lower vs. upper visual field....
In natural environments, head movements are required to search for objects outside the field of view (FoV). Here we investigate the power of a salient target in an extended visual search array to faci...
Optic disc drusen (ODD) are calcified deposits in the prelaminar portion of the optic nerve head. Although often asymptomatic, these deposits can cause progressive visual field defects and vision loss...
This was a retrospective cohort study including 65 eyes of 43 patients with ODD from the Duke Ophthalmic Registry. All eyes had at least 12 months of follow-up and at least 3 reliable standard automat...
Subjects were followed for an average of 7.6 ± 5.3 years. The mean rate of SAP MD change was -0.23 ± 0.26 dB/year, ranging from -1.19 to 0.13 dB/year. Fifty-seven eyes (87.7%) had slow progression (sl...
Most eyes with ODD had slow rates of visual field loss over time. Age and baseline severity were significantly associated with faster rates of visual field loss....
To evaluate the association between baseline severity of visual field (VF) damage and the initial rates of VF progression with quality of life (QOL) outcomes over an extended follow-up in glaucoma....
Retrospective cohort study....
Both eyes of 167 glaucoma or suspected glaucoma patients were followed for 10.0±0.3 years. The National Eye Institute Visual Function Questionnaire (NEI-VFQ)-25 was performed at the end of the follow-...
All models demonstrated association of worse baseline severity of VF damage with worse subsequent NEI-VFQ-25 scores. Faster rates of decline in VF mean deviation of the better eye and the mean sensiti...
Baseline severity and initial rates of change of VF damage are associated with QOL outcomes over an extended follow-up. Assessment of longitudinal VF changes, especially in better eye, provides progno...
To investigate the intereye correlations between and differences in the rates of visual field (VF) progression in eyes with bilateral open-angle glaucoma....
Retrospective, longitudinal, observational study....
Patients with bilateral open-angle glaucoma with 8 or more reliable 30 - 2 standard automated perimetry tests over a period of more than 2 years were enrolled. The rate of change of the MD (MD slope) ...
One hundred eighty-eight eyes from 94 patients (56 women) were enrolled. A significant intereye correlation of the rates of visual field progression (P = .002) was found. The mean ± standard deviation...
A significant intereye correlation in the rate of VF progression was found in eyes with bilateral open-angle glaucoma. We showed the distributions and associated factors of intereye differences in VF ...
To investigate the influence of peripapillary retinoschisis (PRS) on visual field (VF) test results in patients with primary open angle glaucoma (POAG)....
Thirty eyes of 30 patients with POAG who had PRS at least once were included. All eyes were followed-up for a minimum 5 years at 4-6-month intervals. The occurrence of PRS was determined by circumpapi...
Global MD (p=0.345) and regional VF deviations (p=0.255) did not differ significantly between immediately after and just prior to PRS formation. Global MD (p=0.846) and regional VF deviations (p=0.758...
PRS has no short-term effect on the VF sensitivity. Therefore, VF test can still be useful for evaluating glaucomatous damage even in the presence of PRS compared with OCT....
Visual input is not equally processed over space. In recent years, a right visual field advantage during free walking and standing in orientation discrimination and contrast detection task was reporte...